Drug-resistant EGFR mutations promote lung cancer by stabilizing interfaces in ligand-free kinase-active EGFR oligomers.
Iyer RS, Needham SR, Galdadas I, Davis BM, Roberts SK, Man RCH, Zanetti-Domingues LC, Clarke DT, Fruhwirth GO, Parker PJ, Rolfe DJ, Gervasio FL, Martin-Fernandez ML.
Iyer RS, et al. Among authors: davis bm.
Nat Commun. 2024 Mar 19;15(1):2130. doi: 10.1038/s41467-024-46284-x.
Nat Commun. 2024.
PMID: 38503739
Free PMC article.